Eli Lilly (NYSE:LLY) announced today that it agreed to acquire a manufacturing facility from sterile manufacturer Nexus. Buying the FDA-approved facility in Pleasant Prairie, Wisconsin, further expands Lilly’s global parenteral (injectable) manufacturing network. It also supports increased demand for the company’s medicines, Lilly said in a news release. The company expects that production at the…
Genentech, Sanofi both plan to lay off hundreds around San Francisco
Genentech and Sanofi both plan to make significant headcount reductions in the San Francisco area, according to notices filed in the state of California. The San Francisco Chronicle first reported the layoffs. The companies both filed WARN notices to notify the state of their intent to reduce their workforces. Genentech, a Roche unit, will permanently…
Astellas breaks ground on €330M manufacturing facility in Ireland
Astellas Pharma announced that it broke ground on a construction site for a state-of-the-art production facility in Ireland. The company invested €330 million in the facility situated at Kerry Technology Park in Tralee, Co. Kerry. Astellas designed the facility with sustainability front of mind. It expects the plant to accelerate the expansion of its in-house…
MilliporeSigma to invest €300M in new bioprocessing plant in South Korea
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA (Darmstadt, Germany), announced a €300 million in South Korea. The investment goes toward a new bioprocessing production center in Daejon, South Korea. It marks the largest investment by the company’s life science business sector in Asia-Pacific to date. The company expects the investment to…
Lonza buys Genentech manufacturing plant from Roche for $1.2B
Lonza agreed to acquire the Genentech large-scale biologics manufacturing site in Vacaville, California, from Roche for $1.2 billion. The acquisition will increase Lonza’s large-scale biologics manufacturing capacity to meet demand for commercial mammalian contract manufacturing from customers with existing commercial products, plus molecules currently on the path to commercialization within its network. Lonza’s new facility…
Novartis begins $256M Singapore expansion
Novartis announced last week that it broke ground on a biopharmaceutical manufacturing plant in Singapore. The company put forward a $256 million investment to begin the project, which will lead to the deployment of digital and automation solutions to enhance manufacturing productivity, improve operational efficiency, and upskill the workforce. Novartis said this site will focus…
W.R. Grace expands manufacturing plant in Michigan
W.R. Grace announced that it opened an expanded fine chemical contract development and manufacturing plant in Michigan. The Columbia, Maryland-based specialty chemicals company opened the facility in South Haven, Michigan. Following a 21-month project, more than 200 employees joined executives and community leaders for a ribbon-cutting ceremony this week. Grace’s facility has 25% more capacity,…
Could pharma production someday move to space?
Four astronauts ended a six-month science expedition that evaluated the potential of Redwire technology to produce certain crystals for pharmaceuticals. In November, Redwire Corporation announced that its “lab-in-a-box” was installed in an orbiting laboratory following a launch on SpaceX’s 29th Commercial Resupply Services (CRS) mission. The pharmaceutical in-space laboratory (PIL) biocrystal optimization experiment (BOX) aimed…
Telix Pharmaceuticals to buy ARTMS and its isotope production platform
Telix Pharmaceuticals announced that it agreed to acquire radioisotope production technology firm ARTMS Inc. ARTMS also brings with it an advanced cyclotron-based isotope production platform and manufacturing plant. It has a stockpile of ultra-pure rare metals required for consumable target production, too, according to a news release. The company specializes in the physics, chemistry and…
Generic drugs maker Noumed Pharma announces new Australia plant
Noumed Pharmaceuticals says it started construction on a $100 million purpose-built facility in South Australia’s northern suburbs. According to a news release. the company expects this facility to become the most modern of its kind in Australia. The state-of-the-art pharmaceutical manufacturing plant enhances the country’s sovereign supply into the pharmacy and health networks. Noumed plans…